Royalty Report: Drugs, ribonucleic acid, Therapeutic – Collection: 243427

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • ribonucleic acid
  • Therapeutic
  • Diagnostic
  • Disease
  • Diabetes Treatment
  • Genome
  • obesity
  • Drug Discovery
  • Biotechnology
  • Respiratory
  • Vaccine
  • HIV / AIDs
  • Proteins
  • Optical
  • Cancer
  • DNA
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243427

License Grant
The University grants to the Licensee a non-exclusive, worldwide, royalty-bearing license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.  Licensee shall have the right to grant sublicenses.
License Property
The patents are for RNA Sequence-Specific Mediators of RNA Interference.

Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, or, using or incorporating some portion of one or more Biological Materials.

Biological Materials means the tangible biological materials described in the patents, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials.

UMMC 01-36 “RNA Sequence-Specific Mediators of RNA Interference” Inventors David P. Bartel, Philip A. Sharp, Thomas Tuschl, and Philip D. Zamore
I. United States Patents and Application
USSN 60/265232 entitled “RNA Sequence-Specific Mediators of RNA Interference”

USSN 09/821832 entitled “RNA Sequence-Specific Mediators of RNA Interference”
PCT/US01/10188 entitle “RNA Sequence-Specific Mediators of RNA Interference”

Field of Use
The field of use is therapeutics limited to the narrowed fields of other Medical School license agreements; specifically, using RNAi to inhibit HCMV Immediate Early (IE) gene expression in Retinitis applications, using RNAi to inhibit mutant SOD 1 gene expression in Amytrophic Lateral Sclerosis (ALS) applications, and using RNAi to inhibit gene targets implicated in Type II Diabetes and Obesity under the rights of Medical School in any patent rights claiming those inventions.

IPSCIO Record ID: 230809

License Grant
The University Medical School grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.
License Property
Medical School is owner by assignment of the invention claimed in the United States Patent Application pertaining to the Medical Schools invention entitled In Vivo Production of Small Interfering RNAs.

UMMC 02-01 “In Vivo Production of Small Interfering RNAs”
Inventors

Phillip Zamore, Craig Mello, Gyorgy Hutvagner, Juanita McLachlan, and Alla Grishock

Provisional Patent Application filed on July 12, 2001 #60/305,185 entitled “In Vivo Production of Small Interfering RNAs that Mediate Gene Silencing”
U.S. Patent Application filed on July 12, 2002 #10/195,034

Field of Use
The Field means therapeutics, prophylactics, and diagnostics arising from the limited use of RNAi to inhibit HCMV Immediate Early (IE) gene expression in Retinitis applications, using RNAi to inhibit mutant SOD I gene expression in Amyotrophic Lateral Sclerosis (ALS) applications, and using RNAi to inhibit gene targets implicated in Type II Diabetes and Obesity.

IPSCIO Record ID: 294286

License Grant
Licensor grants a non-exclusive right and license under the Licensor Patent Rights for the sole and exclusive purposes of Researching, Developing and Commercializing Licensed RNAi Products for the Target in the Field in the Territory.
License Property
Licensor has intellectual property covering technology useful for the discovery, development, manufacture, characterization, or use of therapeutic products that function through RNA interference (RNAi).

Patents include short double-stranded RNAs as therapeutics.

Licensees target is RTP 801, or, DNA•damage-inducible transcript 4.

Field of Use
Field means the use of therapeutic RNAi Products against the Target for the treatment in humans of ocular diseases, loss of hearing, emphysema and pressure sores.

Emphysema is a long-term, progressive disease of the lungs that primarily causes shortness of breath due to over-inflation of the alveoli (air sacs in the lung). In people with emphysema, the lung tissue involved in exchange of gases (oxygen and carbon dioxide) is impaired or destroyed.

IPSCIO Record ID: 230810

License Grant
The University Medical School hereby grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.
License Property
Medical School is owner by assignment of the invention claimed in the United States Patent Application pertaining to the Medical Schools invention titled Inhibition of Gene Expression in Adipocytes using Interference RNA.

Patent Rights
Docket number UMMC 03-05 Title “ Method of Introducing SI RNA into adipocytes”
Provisional Patent Application Serial number 60/432,427, filed on December 11, 2002.

Field of Use
The Field means drug discovery in type 2 diabetes and/or obesity with therapeutic, prophylactic, or diagnostic applications.

IPSCIO Record ID: 273253

License Grant
Medical School and Licensor each hereby grants to Company and its Affiliates an exclusive, worldwide, royalty-bearing license (with the right to sublicense) under their respective commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.
                                                                    
Medical School hereby grants to Company and its Affiliates a non-exclusive, royalty-bearing license (with the right to sublicense) under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field and Licensor hereby consents to such grant by Medical School.

Licensor hereby grants to Company and its Affiliates the right to acquire a non-exclusive, worldwide, royalty-bearing license (with the right to sublicense) to any Licensor Related Technologies. Licensor shall promptly disclose in writing to Company each of the Licensor Related Technologies at the time such technologies are acquired or licensed by Licensor. Licensor and Company shall negotiate in good faith the terms of the Licensor Related Technologies License.

License Property
United States Provisional Patent Application filed December 3, 2002 serial number 60/430,732 entitled ' Polyvalent, Primary HIV-1 Envelope Glycoprotein DNA Vaccine.

United States Provisional Patent Application filed in September 2003, serial number 60/503/907 entitled 'Polyvalent DNA and Protein Vaccines.'

United States Utility Patent Application filed December 3, 2003 and its foreign counterparts referred to by the parties as the Joint Patent Filing.

Licensed Product means the HIV Vaccine and any product that cannot be developed, manufactured, used, or sold without (a) infringing one or more claims under the Patent Rights, (b) using or incorporating some portion of one or more Biological Materials, or (c) using some portion of the Related Technology.

Biological Materials means certain tangible biological materials that are necessary for the effective exercise of the Patent Rights, which materials are described, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA,  recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials (such as recombinant proteins isolated from a cell extract or supernatant by non-proprietary affinity purification methods). These Biological Materials shall be listed on this agreement, which will be periodically amended to include any additional Biological Materials that Medical School may furnish to Company.

Licensor Related Technologies means any additional technologies outside of the 03-24 Technology and the 03-111 Technology that satisfies all of the following (i) are now or subsequently owned or licensed to Licensor, including any technologies that may be acquired by Licensor pursuant to its option for an exclusive license of the Medical School Subcontract, (ii) result from work done by Medical School under the Medical School Subcontract for a DNA-based HIV vaccine with protein boost, and (iii) are deemed necessary or advantageous by Company for the development or commercialization of the HIV Vaccine.

The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by Medical School and Licensor as UMMC 03-111.

The '03-24 Technology – UMMC 03-24 entitled Primary and Polyvalent HIV-1 Envelope Glycoprotein DNA Vaccines

Field of Use
Field means therapeutics and prophylactics limited to the generation of DNA-based HIV-1 vaccines.

IPSCIO Record ID: 294288

License Grant
Licensor grants a non-exclusive right and license under the Licensor Patent Rights for the sole and exclusive purposes of Researching, Developing and Commercializing Licensed RNAi Products for the Target in the Field in the Territory.
License Property
Licensees target is P53 Tumor protein p53 (Li•Fraumeni syndrome}

Licensor has intellectual property covering technology useful for the discovery, development, manufacture, characterization, or use of therapeutic products that function through RNA interference (RNAi).

Patents include short double-stranded RNAs as therapeutics.

Field of Use
Field means the use of therapeutic RNAi Products against p53 for the treatment of hypoxic injury in humans, including but not limited to renal failure.

Hypoxic injury implies damage to cells resulting only from decreased oxygen tension. This is a relatively unusual pattern of injury in its pure form. Hypoxia can result from decreased atmospheric oxygen concentration, abnormal lung function, and decreased oxygen-carrying capacity in the blood (e.g., severe anemia).

IPSCIO Record ID: 25776

License Grant
The Licensor grants to the Licensee and its Affiliates an exclusive, worldwide license, with the right to sub-license, under the Licensor’s commercial rights in the Patent Rights and Biological Materials to develop, make, use and sell Licensed Products in the field.
License Property
Biological Materials means certain tangible biological materials that are necessary for the effective exercise of the Patent Rights, as well as tangible materials that are routinely produced through use of the original materials, including for example, any progeny derived or produced from a cell line, monoclonal antibodies produced by hybridoma cell, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of DNA or RNA, and substances routinely purified from a source material included in the original materials such as recombinant proteins isolated from a cell extract or supernantant by non-proprietary affinity purification methods.

Pursuant to the new Agreement, the Licensor has granted an exclusive, worldwide,  (with the right to subLicense) License with regard to patents entitled Use of Fused Imidazoles, Aminopyrimidines, Isonicotinamides, Aminomethyl Phenoxypiperidines and Aryloxypiperidines to Promote and Detect Endogenous Neurogenesis (U.S. Patent Application No. 10/914,460 ); and Methods for Discovering Neurogenic Agents ( U.S. Patent Application No. 10/728,652 ).

Field of Use
Field means the use of compounds as therapeutic agents to treat diseases in humans and animals in all therapeutic categories including, without limitation  Category I, which is limited to psychiatric disorders, mood disorders, depression, post-traumatic stress syndrome, anxiety, panic disorder, bipolar and unipolar disorders, delusional disorders, and schizophrenia;  Category II, which includes Alzheimer’s Disease and Parkinson’s Disease;  and Category III, which includes diabetes and its complications, including the neurological complications of peripheral neuropathies, static and progressive dementias and hypokinetic movement disorders.

IPSCIO Record ID: 233428

License Grant
University hereby grants to Company and its Affiliates an exclusive, worldwide license,with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.

University hereby grants to Company and its Affiliates a non-exclusive license, with the right to sublicense, under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field.

License Property
The patents are for RNAi Targeting of Viruses.  Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, using or incorporating some portion of one or more Biological Materials, or using some portion of the Related Technology.

Biological Materials means certain tangible biological materials that are necessary for the effective exercise of the Patent Rights.

Related Technology means any know-how, technical information, research and development information, test results, and data necessary for the effective exercise of the Patent Rights which has been developed in the laboratory at the Medical School as of the Effective Date and which is owned by Medical School.

UMMC 03-17 “RNAi Targeting of Viruses”

Field of Use
The Field means the limited use of RNAi to inhibit human cytomegalovirus (HCMV) Immediate Early (IE) gene expression for the development of retinitis prophylactics, therapeutics, and diagnostics.

IPSCIO Record ID: 233431

License Grant
University grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.

University grants to Company and its Affiliates a non-exclusive license, with the right to sublicense, under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field.

License Property
The patent is for Selective Silencing of a Dominant ALS Gene by RNAi.  Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, using or incorporating some portion of one or more Biological Materials, or using some portion of the. Related Technology.

Related Technology means any know-how, technical information, research and development information, test results, and data necessary for the effective exercise of the Patent Rights.

Docket number UMMC 03-60 Title “Selective Silencing of a Dominant ALS Gene by RNAi”
Patent Application Serial number 60/423,507, filed on November 4, 2002

Field of Use
The Field means inhibition of mutant superoxide dismutase (SODI) gene expression for the treatment of amyotrophic lateral sclerosis (ALS) including therapeutics, prophylactics and diagnostics.

IPSCIO Record ID: 300745

License Grant
Licensor grants the Japanese Licensee a license under and to Licensor Technology to Develop and Commercialize the Licensed Product in the Field in the Licensee Territory. Such license is exclusive for the Royalty Term of the Licensed Product in each country in the Licensee Territory, and shall thereafter be a non-exclusive, fully-paid license to Develop, Manufacture and Commercialize the Licensed Product in the Field in such country.

For the Manufacturing License, Licensor grants a non-exclusive license under Licensor Technology solely for the purpose of Manufacturing the Licensed Product for the Licensee Territory and Licensee grants Licensor a non-exclusive license under Licensee Technology to Manufacture the Licensed Product.

License Property
Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus (RSV) that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

Antisense Product means a single-stranded oligonucleotide or analog thereof having a specific sequence that inhibits protein synthesis at the nucleic acid level by specifically binding to the sequence of a messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing selective inhibition of gene expression.

The patents include, but are not limited to; RNA interference is mitigated by 21 and 22nt small RNAs;  RNA interference mediating small RNA molecules;  RNA sequence-specific mediators of RNA interference; and, Inhaled treatment for RSV.

Field of Use
Licensee enters this agreement for the treatment of respiratory infections in humans caused by RSV, in Japan and certain other countries in Asia.
RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract.

IPSCIO Record ID: 344567

License Grant
Licensor grants
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.

For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.

For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.

License Property
Patents includes, among other
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.

Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).

ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.

Licensed Products means any RNAi Product directed to RSV.

RSV means all strains of the respiratory syncytial virus.

RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.

RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.

Field of Use
ALN-RSV01 is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies.

Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.

Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.

IPSCIO Record ID: 352695

License Grant
University grants an exclusive, worldwide license in the Patent Rights to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Field.
License Property
The patents include
–  Allele-specific RNA Interference;
–  In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
–  RNA Interference for the Treatment of Gain-of-Function Disorders;
–  Novel AAVs and Uses Thereof;
–  CNS Targeting AAV Vectors and Methods of Use Thereof;
–  Methods and Compositions for Controlling Efficacy of RNA Silencing;
–  Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
–  Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
Field of Use
The Field of use is the treatment of human diseases using gene therapy applications.  Any commercial sale of research reagents covered by the Patent Rights is specifically excluded
from the Field.

The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.

The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.

IPSCIO Record ID: 299237

License Grant
Licensor hereby grants to Licensee
— a non-exclusive license under the Patent Rights, to make, have made, use, and/or sell Licensed Products for human and non-human applications;
— the right under the Patent Rights to grant to an Affiliate a sublicense; and,
— the right under the Patent Rights to grant to Product Development Partner(s) a single sublicense for each specific application of Licensed Product.
License Property
The patent properties cover the T7 technology, such as, Cloning and Expression of the Gene for Bacteriophage TI RNA Polymerase.

The Designated Product shall mean a protein or other product produced through use of the T7 technology.

SGN-10 is a single-chain immunotoxin that binds to cancer cells and kills them by delivering a protein toxin inside the cell. SGN-10 is composed of the receptor binding portion of the BR96 monoclonal antibody and a truncated portion of a protein toxin called  Pseudomonas    exotoxin A. SGN-10 is currently in two phase I clinical trials.

The term 'Patent Rights' shall mean
    1.  United States Patent No. 4,952,496 entitled 'Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase', and any reissue thereof;

    2.  U.S. Patent No. 5,693,489 entitled 'Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase', and any reissue thereof;

Field of Use
The field of use is to produce anti-cancer products.

IPSCIO Record ID: 289173

License Grant
Party A, a Canadian University, hereby assigns to Licensee all of Party A’s right, title and interest in and to U.S. Patent Application No. 11/807,872, with no additional payment due to Party B and will record such assignment with the U.S. Patent and Trademark Office.

The Parties shall direct their respective counsel to execute Stipulations of Dismissal with Prejudice dismissing all claims and counterclaims that were or could have been asserted in the Massachusetts State Court Action, U.S. Infringement Action, Canadian Infringement Action, and B.C. Action, and in the case of the Interference Proceeding, a Request for Adverse Judgment providing that Licensee concedes priority to Party A with respect to all claims that correspond to Counts 1-5, i.e., claims 34, 36, 38, and 40-43 of Party A U.S. Application 11/807,872; claims 1-6, 8, 10, 12-18, 21-22, and 32-33 of Licensee U.S. Patent 7,718,629; and claims 32-38 of Licensee U.S. Application 13/165,568, and requesting that an adverse judgment be entered against Licensee as to these claims and priority be awarded to Party A for U.S. Application 11/807,872.

License Property
U.S. Patent 7,718,629 – Compositions and methods for inhibiting expression of Eg5 gene
Patent certains to intellectual property (IP) elements related to lipid nanoparticle (LNP) technology for RNAi therapeutics.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development.

Field of Use
By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon.

IPSCIO Record ID: 230807

License Grant
For the License Grants of Patent Rights and Biological Materials, the University/Medical School grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field and to develop and perform Licensed Services in the Field.

For the Related Technology, Medical School grants to Company and its Affiliates a non-exclusive, license, with the right to sublicense, under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field and to develop and perform Licensed Services in the Field.

License Property
Patents include Method of Introducing SI RNA into adipocytes, Genes Expressed in Type II diabetes and Uses Thereof, and, Receptor-Activated Reporter Systems.  Related  Technology  means  know-how,  technical  information, research and development  information,  test results, and data necessary for the
effective  exercise of the Patent  Rights which are owned by the Medical  School.

Licensed Product means any Covered Product or Developed Product.

Covered Product means any product that cannot be manufactured, used, or sold without infringing one or more claims under the Patent Rights, incorporates some portion of one or more Biological Materials proprietary to Medical School, or  cannot be manufactured, used, or sold without using some portion of the Related Technology.

Developed Product means any product that is not a Covered Product and is developed using methods claimed in the Patent Rights or using some material portion of the Related Technology.

Licensed Service means any service that cannot be developed or performed without using at least one process that infringes one or more claims under the Patent Rights,  uses some portion of one or more Biological Materials, or  uses some portion of the Related Technology.

Field of Use
Field means drug discovery in type 2 diabetes and/or obesity with therapeutic, prophylactic, or diagnostic applications and products for treatment, prevention or diagnosis of type 2 diabetes and/or obesity.

IPSCIO Record ID: 248389

License Grant
University grants to Company an exclusive, worldwide, license in the Patent Rights to make, have made, use, offer to sell, sell, have sold and imported Licensed Products in the Field, including research for development of Licensed Products.
License Property
University owns intellectual property rights which relate to therapeutic applications of RNAi, as described in Universitys invention disclosure UMMC 03-75, entitled Gene Silencing with siRNA Containing Mismatches to Targets A New Method to Cure Allele Specific Genetic Diseases and Disorders.
Field of Use
The Field means Primary Field and Secondary Field collectively. Any commercial sale of research reagents covered by the Patent Rights is specifically excluded from the Field.

Primary Field means therapeutic, prophylactic, or diagnostic health care applications for amyotrophic lateral sclerosis (ALS), diabetes, and obesity, in humans.

Secondary Field means therapeutic, prophylactic, or diagnostic health care applications in humans that are not included in the Primary Field.

IPSCIO Record ID: 227264

License Grant
This agreement is to have the Invention perfected and marketed as soon as possible so that resulting products may be available for public use and benefit.

The University grants a license in the Licensed Field of Use to make, have made, use, have used, sell, have sold, import and have imported Licensed Product in the Licensed Territory.

This agreement is co-exclusive, with co-exclusive meaning that Licensor will only grant one further
license in the Licensed Territory in the Licensed Field of Use.  Should the other grant be terminated, then this agreement will be considered exclusive.

License Property
The patents and invention are for
– Efficient RNA Transfection to the Livers of Living Mice,
– Methods and Compositions for In Vivo Delivery of a Naked Ribonucleic Acid Into a Target Cell, and,
– Methods and Compositions for RNAi Mediated Inhibition of Viral Gene Expression in Mammals.

siRNA Molecule means an agent that modulates expression of a target gene by an RNA interference mechanism.

Field of Use
The Licensed Field of Use means delivery of ex-vivo synthesized siRNA Molecules for research, development and therapeutic uses (including a diagnostic necessary for development, sale or reimbursement of a therapeutic Licensed Product). The Licensed Field of Use specifically excludes delivery of any system producing in vivo expressed siRNAs for therapeutic use, including but not limited to episomal and integrated vectors, and recombinant viruses.

IPSCIO Record ID: 279354

License Grant
Licensor grants to Irish Licensee an exclusive license under the Licensor Patents to make (subject to Licensor’s manufacturing rights set forth below), use, sell, and offer for sale in any country of the world Licensed Products in the Field. Neither Licensee nor Licensor will have the right to develop or commercialize Licensed Products outside the Field without prior written consent of the other Party.

Licensor grants to Licensee (a) an exclusive license to use in any country of the world any method or composition claimed by the Licensor Patents, and (b) a non-exclusive license to use in any country of the world any Licensor Know-How, to research in the Field Lead Compounds, Development Compounds, Backup Compounds, and Licensed Products.

License Property
Licensed Product means a Development Compound for which the Parties obtain the approval from any Regulatory Authority to sell for use by the general public in the Field.

Licensor Patents means a) the patents and applications listed; b) any application that claims priority to the foregoing patents and applications; and c) any patent that issues from any of the applications described in clauses a) and b) above.
US Patent #6,506,559 – Genetic inhibition by double-stranded RNA
US Patent #6,117,657 – Non-nucleotide containing enzymatic nucleic aci
US Patent #6,586,238 – Enzymatic nucleic acids containing 5-and or 3-cap structures

Lead Compound is a Lead selected by JSC for evaluation in the Field.

Development Compound means a Pre-Development Compound that the JSC has designated for clinical development.

Compound means a composition comprising one or more siNAs as active ingredients, known as of the Effective Date or discovered pursuant to this Agreement subsequent to that date, against the Licensee Named Targets in the Field.

Backup Compound means a Lead Compound that the JSC has selected as a backup candidate for clinical development.

JSC means the Joint Steering Committee.

Field of Use
Field means conditions and diseases affecting the eve and treatments for such conditions and diseases. Such conditions and diseases include, for example, diabetic retinopathy and ocular adenoviral infection, but this does not mean that the Field encompasses the treatment outside the eye of diabetes or adenoviral infection, respectively.

Licensee is to develop Sirna-027, a RNAi-based therapeutic currently in Phase 1 for age-related macular degeneration (AMD), and to discover and develop other RNAi-based therapeutics against select gene targets in ophthalmic diseases.

IPSCIO Record ID: 223124

License Grant
Licensor, a non-profit institution, hereby grants to Licensee and its Affiliates a worldwide, non-exclusive license, under Licensor Know-How and Licensed Patents (I) for all internal research and development purposes, including without limitation, the right to make, use and import Licensor Know How and inventions claimed in the Licensed Patents and (ii) to develop, make, use, market, sell, offer for sale, export and import, in the Field of Use, Licensed Products, including without limitation those covered by Valid Claims in the Licensed Patents.
License Property
Intellectual property relates to the induction of gene silencing in mammalian cells through RNAi.

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing specific genes, an ability that could become the basis for a whole new class of therapeutic products. The discovery of RNAi has been heralded by many as a major breakthrough, and the journal Science named RNAi the top scientific achievement of 2002 as well as one of the top ten scientific advances of 2003. Because many diseases are caused by the inappropriate activity of specific genes, the ability to silence such genes selectively through RNAi could provide a means to treat a wide range of human diseases.

Licensed Patents means the U.S. Patent Applications listed below and any divisions, continuations, reissues, reexamines, extensions and continuations-in-part applications thereof and any patents issuing thereto; and any and all foreign patents, foreign applications, extensions and supplemental protection certificates or patent applications corresponding thereto having the Principal Investigator as an inventor and claiming the same priority date as a parent application.

Licensor Patents
Serial No.                  Type      Tite                                                                                       Date            Filed Status
PCT/US01/08435      PCT      Methods and Compositions for RNA Interference       3/16/01       Published
09/858,862                CIP       Methods and Compositions for RNA Interference       5/16/01       Pending
09/866,551                CIP       Methods and Compositions for RNA Interference       5/24/01       Pending
10/055,797                CIP       Methods and Compositions for RNA  Interference      1/22/02       Pending

Licensed Product means any product, including but not limited to any lyophilized liquid, sustained release or aerosolized formulation or other formulation, or process for which Licensee, or its Affiliate has received FDA Approval and/or Regulatory Approval, which is made through the use of Licensor Know-How or falls within the scope of a Valid Claim of a Licensed Patent.

Field of Use
The field of Use means all therapeutic uses in humans, including without limitation the diagnosis, prevention and treatment of diseases or conditions and all other healthcare applications. Field of Use shall not include research reagent sales.

IPSCIO Record ID: 289256

License Grant
Licensor will grant to Canadian Licensee a non-exclusive license to any Licensor Intellectual Property for use in RNAi Products.
License Property
Licensed Product means any product, good, or service covered by a claim of the Licensor controlled Intellectual Property or Licensee controlled Intellectual Property.

RNAi Product means a product containing, comprised of or based on siRNA, Dicer Substrates, Multivalent RNA, or any derivatives thereof, which are effective in gene function modulation and designed to modulate the function of particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or siRNA derivatives or moieties are complementary. For greater clarity, an RNAi Product shall not include Antisense.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals.

LNP intellectual property for use in RNAi therapeutic products using LNP technology.

LNP technology relates to where RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Licensor’s LNP platform is being utilized in multiple clinical trials.  LNP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.

siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin.

Supplemental Field Product means a product containing, comprised of, or based on Antisense or Gene Therapy.

Field of Use
Field of Use means the delivery of an RNAi Product for any and all purposes.

Supplemental Field means the delivery of (i) single-stranded oligonucleotides, either chemically modified or unmodified, acting through the RNase H mechanism or by or other mechanisms of translational arrest but excluding RNA interference involving RISC (“Antisense”) and (ii) DNA plasmids or messenger RNA (mRNA) either chemically modified or unmodified that are transcribed and/or translated into protein and wherein the pharmacological activity is dependent on expression of the protein (Gene Therapy).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.